BUSINESS
Motilal Oswal pumps $72 million into Hyderabad-based medtech Sensa Core
The company will use the capital to expand capacity at a new facility in Hyderabad’s Medical Device Park, aimed at scaling production and introducing next-gen point-of-care products
BUSINESS
Medicover’s India arm aiming for 2026 IPO to unlock value in Swedish giant’s fastest-growing market
The move comes as the hospital chain is set to get its 25th hospital operational, capping a growth sprint during which it has deployed around Rs 2,000 crore over the last seven years to build a 6,000-bed network
BUSINESS
Corex cough syrup gets Cipla boost as Pfizer strikes exclusive India deal
The agreement gives Cipla sole rights to sell and distribute the two Corex variants along with some other drugs Pfizer will continue to manufacture and supply the products
BUSINESS
Narayana Health plans to export high-volume, low-cost care model to UK and beyond
“We’ve built the world’s most efficient healthcare model in India. Now we want to apply that in markets where everyone is insured and cost-cutting is critical,” Vice Chairman Viren Shetty said in an interview to Moneycontrol.
BUSINESS
IHH sets stage for growth, integration as Fortis open offer closes
The completion of the open offers — delayed for years amid litigation tied to the erstwhile Fortis promoters and Daiichi Sankyo — removes a long‑standing uncertainty for IHH’s India plans
BUSINESS
Explainer: Novo Nordisk’s two-brand bet, how Ozempic and Wegovy are carving India’s GLP-1 market
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, reflecting the company’s effort to capture two massive but different patient pools, sometimes with significant overalap.
BUSINESS
Novo Nordisk launches Ozempic in India against diabetes for Rs 2,200 per week entry dose
The pre-filled pen, which consists of four doses of 0.25mg injection required for initiation, costs Rs.8800 per month (Rs,2200 per week), 0.5 mg per month costs Rs.10,170 (Rs.2542.5 per week) and 1mg costs Rs.11,175 (Rs 2793.75 per week).
BUSINESS
Urban elites drive GLP-1 weight loss boom; distribution deals, price cuts can change script
Mumbai, Delhi and Bengaluru alone account for one-third of GLP-1 sales. Analysts cite affordability, accessibility and awareness as key reasons for the weight loss drugs' limited penetration.
TRENDS
Weight loss GLP-1 drugs craze drives new packages with diagnostics, lifestyle coaching, and drug delivery
The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with diet plans, lab monitoring, and strength training, patients will achieve safer, sustained results.
BUSINESS
After Dr Reddy's, Sun Pharma gets Delhi High Court nod to make, export semaglutide
Sun Pharma, like Dr Reddy's Lab, can't sell semaglutide-based products in India until March 2026 when Novo Nordisk’s patent expires
BUSINESS
Novo moves court to restrain Sun Pharma, Alkem from manufacture, sale of weight loss drug semaglutide
The fresh plea follows a recent court order allowing Dr. Reddy’s Laboratories (DRL) to continue manufacturing and exporting its version of semaglutide while prohibiting domestic sales until Novo Nordisk’s patent expires.
BUSINESS
Zydus to enter US biosimilar market via Keytruda partnership with Germany's Formycon
The move is significant because Keytruda, one of the world’s top-selling immunotherapies with annual sales exceeding $20 billion, faces a looming patent expiry in 2028 in the US, opening the door for biosimilar competition in a market dominated by high-cost oncology drugs.
TRENDS
Asthma, COPD drug sales hit a 3-year high in November as north India chokes on toxic air
The anti-asthma and COPD segment grew 10 percent year-on-year in November, outpacing historical winter trends and marking its strongest performance for the month since 2022, Pharmatrac data shows
BUSINESS
Mounjaro retains top spot in India’s weight-loss market; Wegovy makes steady gains after price cuts
In November, Mounjaro clocked Rs 108 crore in sales, making it the number 1 brand in the IPM, reflecting sustained momentum despite rising competition
BUSINESS
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake
“When we created Biocon Biologics as a separate entity, the objective was clearly to attract investments and build global scale in biosimilars. We did that successfully, even acquiring Viatris’ biosimilars business for $3 billion. But markets kept devaluing both Biocon and Biocon Biologics because of debt overhang and holding company discount. Folding Biologics back into Biocon unlocks true value and gives us a much stronger balance sheet,” Mazumdar-Shaw said.
BUSINESS
Aurobindo Group in mega infra push, to develop Kakinada port, SEZ as industrial-logistics hub
The aim is to make Kakinada a multi-product logistics hub. ‘This is not just ships coming and going — it’s a 50-year vision,’ Kakinada Gateway Port Ltd MD Ram Reddy Ojili tells Moneycontrol
BUSINESS
Bombay High Court rejects Lilavati Trust’s Rs 17 Crore recovery claim for lack of statutory consent
The court held that the trust failed to comply with Sections 50 and 51 of the MPT Act, which require prior approval for suits involving trustees and public trust property.
BUSINESS
Indian pharma eyes US biosimilars boom as USFDA eases rules
The US biosimilars market is projected to balloon from about $22.6 billion in 2025 to more than $90 billion by 2034, according to industry estimates.
BUSINESS
Delhi High Court allows Dr Reddy’s to make weight-loss drug for exports
The company, however, cannot sell the drug in the country till March 2026, when Novo Nordisk’s secondary patent expires
BUSINESS
Wockhardt’s Zaynich NDA gets USFDA acceptance: What India’s first NCE means for the company
The next critical steps in the USFDA process involve a rigorous on-site evaluation: "visiting manufacturing facilities, inspecting documents, and so on".
BUSINESS
“Very confident of positive outcome”: Habil Khorakiwala on USFDA acceptance of Wockhardt’s NDA for its novel antibiotic
Khorakiwala said the Mumbai-based drugmaker is already laying groundwork for commercialization, with options ranging from solo marketing to partnerships in the US.
TRENDS
Cipla’s respiratory push: Sets up diagnostic centre in Delhi, Mumbai and other cities next
Cipla's wants to create awareness, help diagnostics, provide solutions and rehab support, COO Achin Gupta tells Moneycontrol, as the firm doubls down on its lung-care strategy
BUSINESS
Rainbow Hospitals targets 3,165 beds by FY29, eyes high-birth North India as key growth engine
'North India is where the future demand lies, 60% of India’s 28.5 million annual births happen in UP, Bihar, Rajasthan and Haryana,' said Dr. Ramesh Kancharla, Chairman and MD in an interview to Moneycontrol
TRENDS
Civil society groups push back as govt agencies mull data exclusivity in drug rules
Civil society groups, in a letter to Health Minister J.P. Nadda and Commerce Minister Piyush Goyal, urged the government to reject the proposal, arguing it would extend monopolies beyond the 20-year patent term and inflate drug prices.
